Drug intelligence / Profile preview

BI 661051

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 661051 is a small molecule inhibitor developed by Boehringer Ingelheim. It is designed to bind to specific intracellular targets and modulate their activity, though the precise molecular target and mechanism of action have not been publicly disclosed. The drug has undergone Phase 1 clinical trials in healthy male volunteers to assess its safety, tolerability, and pharmacokinetics when administered orally as both a solution and tablet formulation. There are no reported active indications or therapeutic areas beyond these early-stage studies[1][2][4].

Beyond the preview

Go deeper on BI 661051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 661051.

Explore the full profile